BRAF and metastatic melanoma: Of note, a recruiting phase II clinical trial (NCT04633902) will evaluate the use of pembrolizumab with Olaparib and its clinical efficacy in treating metastatic melanoma that has been refractory to ICI and BRAF inhibitors treatment (60).